Clinical Trial Update: QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine [Phase 2]

View source ↗

Summary

ImmunityBio's Phase 2 trial of the NANT Neoadjuvant TNBC Vaccine for triple-negative breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• NANT Neoadjuvant TNBC Vaccine (NANT Neoadjuvant TNBC Vaccine)

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Triple Negative Breast Cancer (TNBC) | Phase 2 | Status: WITHDRAWN